The library is adapted for screening with phage display and strives to meet the rising demand for effective antibodies for a broad range of applications.
Read MoreThe company’s latest covid-19 products include a protein-coated RNA process control, and an in vitro diagnostics control with pooled gene targets.
Read MoreThe new solution is designed to enable laboratories to enter biospecimens into a biobank and rapidly begin conducting covid-19-related testing and research.
Read More
Microproof SARS-CoV-2 screening/identification kits run on many commonly used real-time PCR instruments. The test returns results in less than 1.5 hours.
Read More
Genalyte currently has the capacity to test 250,000 patients per month; the company is scaling up to test more than 7,500,000 patients per month by September.
Read More